JGJ. Raphael Gibbs

J. Raphael Gibbs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


J. Raphael Gibbs has a total of 170 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    IntermediateHTTCAG repeats worsen disease severity in amyotrophic lateral sclerosis

    by Maurizio Grassano, Antonio Canosa, Sandra D’aLfonso, Lucia Corrado, Giorgia Brodini, Emanuele Koumantakis, Paolo Cugnasco, Umberto Manera, Rosario Vasta, Francesca Palumbo, et al.

    Recent research has indicated a connection between amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD), an inherited neurological condition caused by a trinucleotide CAG repeat expansion within exon 1 of the Huntingtin gene (HTT; MIM:613004).1 The same pathogenic CAG repeat expansions (40 or more CAG repeats) observed in patients with HD have been identified in patients with frontotemporal dementia (FTD)/ALS.1 Similarly, non-pathogenic intermediate-length CAG repeats in the ATXN2 gene are a well-established factor associated with increased ALS risk and faster disease progression.2 Given these observations, we investigated the impact of intermediate HTT alleles on survival in two cohorts of patients diagnosed with ALS.


  • Open Access

    A SINE-VNTR-Alu in the LRIG2 Promoter Is Associated with Gene Expression at the Locus

    by Ashley Hall, Anni K. Moore, Dena G. Hernandez, Kimberley J. Billingsley, Vivien J. Bubb, John P. Quinn, NABEC (North American Brain Expression Consortium)

    The hominid SINE-VNTR-Alu (SVA) retrotransposons represent a repertoire of genomic variation which could have significant effects on genome function. A human-specific SVA in the promoter region of the gene leucine-rich repeats and immunoglobulin-like domains 2 (LRIG2), which we termed SVA_LRIG2, is a common retrotransposon insertion polymorphism (RIP), defined as an element which is polymorphic for its presence or absence in the genome. We hypothesised that this RIP might be associated with differential levels of expression of LRIG2. The RIP genotype of SVA_LRIG2 was determined in a subset of frontal cortex DNA samples from the North American Brain Expression Consortium (NABEC) cohort and was imputed for a larger set of that cohort. Utilising available frontal cortex total RNA-seq and CpG methylation data for this cohort, we observed that increased allele dosage of SVA_LRIG2 was non-significantly associated with a decrease in transcription from the region and significantly associated with increased methylation of the CpG probe nearest to SVA_LRIG2, i.e., SVA_LRIG2 is a significant methylation quantitative trait loci (mQTL) at the LRIG2 locus. These data are consistent with SVA_LRIG2 being a transcriptional regulator, which in part may involve epigenetic modulation.


  • Open Access

    The Parkinson’s Disease DNA Variant Browser

    by Jonggeol J. Kim, Mary B. Makarious, Sara Bandres-Ciga, J. Raphael Gibbs, Jinhui Ding, Dena G. Hernandez, Janet Brooks, Francis P. Grenn, Hirotaka Iwaki, Andrew B. Singleton, et al.

    Parkinson’s disease (PD) is a genetically complex neurodegenerative disease with ~20 genes known to contain mutations that cause PD or atypical parkinsonism and 90 common genetic risk factors. Large-scale next-generation sequencing projects have revolutionized genomics research. Applying these data to PD, many genes have been reported to contain putative disease-causing mutations. In most instances, however, the results remain quite limited and rather preliminary, in large part because of an inability of any single group to validate findings in a large independent series of sequenced patients. We present here the Parkinson’s Disease Sequencing Browser: a Shiny-based web application that presents comprehensive summary-level frequency data from multiple large-scale genotyping and sequencing projects. The data is aggregated and involves a total of 102,127 participants, including 30,103 PD cases (including 1,650 proxy cases) and 72,024 controls. Our aim is to assist researchers on their search for PD-risk genes and variant candidates with an easily accessible and open summary-level genomic data browser for the PD research community, https://pdgenetics.shinyapps.io/VariantBrowser/ .


  • Open Access

    Replication assessment of NUS1 variants in Parkinson’s Disease

    by Bernabe I. Bustos, Sara Bandres-Ciga, J. Raphael Gibbs, Dimitri Krainc, Niccolo E. Mencacci, Ziv Gan-Or, Steven J. Lubbe

    The NUS1 gene was recently associated with Parkinson’s disease (PD) in the Chinese population. Here, as part of the International Parkinson’s Disease Genomics Consortium (IPDGC), we have leveraged large-scale PD case-control cohorts to comprehensively assess the NUS1 association in individuals of European descent. Burden analysis of rare nonsynonymous damaging variants across case-control individuals from whole-exome and -genome datasets did not find evidence of NUS1 association with PD. Overall, single variant tests for rare (MAF0.01) variants, including 15 PD-GWAS cohorts and summary statistics from the largest PD GWAS meta-analysis to date, also did not uncover any associations. Our results indicate a lack of evidence for a role of rare damaging nonsynonymous NUS1 variants in PD in unrelated case-control cohorts of European descent, suggesting that the previously observed association could be driven by extremely rare population-specific variants.

  • Open Access

    Biomarkers of Parkinson's Disease: Screening Vital Signs and Routine Blood Tests

    by Hirotaka Iwaki, Hampton L. Leonard, Sara Bandres Ciga, Cornelis Blauwendraat, Mary B. Makarious, Sonja W. Scholz, Noriko Nishikawa, Faraz Faghri, Mark Frasier, J. Raphael Gibbs, et al.

    BACKGROUND: There is a need for reliable, objective, and easily accessible biomarkers for Parkinson's disease. OBJECTIVES: The purpose of this study was to screen biomarkers from vital signs and routine blood tests. METHODS: Longitudinal data of up to 7 years of vital signs and routine blood tests from 418 patients with Parkinson's disease (PD) untreated at baseline and 185 individuals without any neurological disease were analyzed using linear mixed models. We nominated the biomarkers whose main associations with the measurements were significant as differentiating biomarkers. Similarly, we nominated the interaction effects between biomarkers and time from baseline as progression biomarkers. We tested for 49 biomarkers, and multiple comparison was corrected with the false-discovery-rate of 0.05. We further evaluated the potential biomarkers with regard to their importance in diagnosis prediction and their association with sub-scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). We also assessed the relationship of the associations using bioinformatics. RESULTS: Heart rate, systolic blood pressure, white blood cell fractions, neutrophil counts, serum albumin, sodium and AST were different between PD and controls. The causality or genetic correlations of these biomarkers to PD were not observed. Chronological changes in height, albumin, hemoglobin, and bicarbonate were different in PD. These biomarkers were associated with MDS-UPDRS sub-scores. Conclusions In this study, the potential of some easily accessible biomarkers for diagnosis and disease progression was presented. Further investigation of the mechanisms underlying these associations is important for a deeper understanding of the disease and the better management of patients.


  • Open Access

    Large-scale pathway-specific polygenic risk, transcriptomic community networks and functional inferences in Parkinson disease

    by Sara Bandres-Ciga, Sara Saez-Atienzar, Jonggeol Jeff Kim, Mary Makarious, Faraz Faghri, Monica Diez-Fairen, Hirotaka Iwaki, Hampton Leonard, J Botia, Mina Ryten, et al.

    Polygenic inheritance plays a central role in Parkinson disease (PD). A priority in elucidating PD etiology lies in defining the biological basis of genetic risk. Unraveling how risk leads to disruption will yield disease-modifying therapeutic targets that may be effective. Here, we utilized a high-throughput and hypothesis-free approach to determine biological pathways underlying PD using the largest currently available cohorts of genetic data and gene expression data from International Parkinson’s Disease Genetics Consortium (IPDGC) and the Accelerating Medicines Partnership - Parkinson’s disease initiative (AMP-PD), among other sources. We placed these insights into a cellular context. We applied large-scale pathway-specific polygenic risk score (PRS) analyses to assess the role of common variation on PD risk in a cohort of 457,110 individuals by focusing on a compilation of 2,199 publicly annotated gene sets representative of curated pathways, of which we nominate 46 pathways associated with PD risk. We assessed the impact of rare variation on PD risk in an independent cohort of whole-genome sequencing data, including 4,331 individuals. We explored enrichment linked to expression cell specificity patterns using single-cell gene expression data and demonstrated a significant risk pattern for adult dopaminergic neurons, serotonergic neurons, and radial glia. Subsequently, we created a novel way of building de novo pathways by constructing a network expression community map using transcriptomic data derived from the blood of 1,612 PD patients, which revealed 54 connecting networks associated with PD. Our analyses highlight several promising pathways and genes for functional prioritization and provide a cellular context in which such work should be done.


  • Open Access

    The Parkinson’s Disease GWAS Locus Browser

    by Francis P. Grenn, Jonggeol J. Kim, Mary B. Makarious, Hirotaka Iwaki, Anastasia Illarionova, Kajsa Brolin, Jillian H. Kluss, Artur F. Schumacher-Schuh, Hampton Leonard, Faraz Faghri, et al.

    Parkinson’s disease (PD) is a neurodegenerative disease with an often complex genetic component identifiable by genome-wide association studies (GWAS). The most recent large scale PD GWASes have identified more than 90 independent risk variants for PD risk and progression across 80 loci. One major challenge in current genomics is identifying the causal gene(s) and variant(s) from each GWAS locus. Here we present a GWAS locus browser application that combines data from multiple databases to aid in the prioritization of genes associated with PD GWAS loci. We included 92 independent genome-wide significant signals from multiple recent PD GWAS studies including the PD risk GWAS, age-at-onset GWAS and progression GWAS. We gathered data for all 2336 genes within 1Mb up and downstream of each variant to allow users to assess which gene(s) are most associated with the variant of interest based on a set of self-ranked criteria. Our aim is that the information contained in this browser ( https://pdgenetics.shinyapps.io/GWASBrowser/ ) will assist the PD research community with the prioritization of genes for follow-up functional studies and as potential therapeutic targets.


  • Open Access

    Common variation at the LRRK2 locus is associated with survival in the primary tauopathy progressive supranuclear palsy

    by Edwin Jabbari, Manuela M.X. Tan, Regina H. Reynolds, Kin Y. Mok, Raffaele Ferrari, David P. Murphy, Rebecca R. Valentino, Owen A. Ross, Dennis W. Dickson, Safa Al-Sarraj, et al.

    The genetic basis of variation in the rate of disease progression of primary tauopathies has not been determined. In two independent progressive supranuclear palsy cohorts, we show that common variation at theLRRK2locus determines survival from motor symptom onset to death, possibly through regulation of gene expression. This links together genetic risk in alpha-synuclein and tau disorders, and suggests that modulation of proteostasis and neuro-inflammation by LRRK2 inhibitors may have a therapeutic role across disorders.

  • Open Access

    Genetic variation within genes associated with mitochondrial function is significantly associated with later age at onset of Parkinson disease and contributes to disease risk

    by Kimberley J. Billingsley, Ines A. Barbosa, Sara Bandrés-Ciga, John P. Quinn, Vivien J. Bubb, Charu Deshpande, Juan A. Botia, Regina H. Reynolds, David Zhang, Michael A. Simpson, et al.

    Mitochondrial dysfunction has been implicated in the aetiology of monogenic Parkinson’s disease (PD). Yet the role that mitochondrial processes play in the most common form of the disease; sporadic PD, is yet to be fully established. Here we comprehensively assessed the role of mitochondrial function associated genes in sporadic PD by leveraging improvements in the scale and analysis of PD GWAS data with recent advances in our understanding of the genetics of mitochondrial disease. First, we identified that a proportion of the “missing heritability” of the PD can be explained by common variation within genes implicated in mitochondrial disease (primary gene list) and mitochondrial function (secondary gene list). Next we calculated a mitochondrial-specific polygenic risk score (PRS) and showed that cumulative small effect variants within both our primary and secondary gene lists are significantly associated with increased PD risk. Most significantly we further report that the PRS of the secondary mitochondrial gene list was significantly associated with later age at onset. Finally, to identify possible functional genomic associations we implemented Mendelian randomisation, which showed that 14 of these mitochondrial function associated genes showed functional consequence associated with PD risk. Further analysis suggested that the 14 identified genes are not only involved in mitophagy but implicate new mitochondrial processes. Our data suggests that therapeutics targeting mitochondrial bioenergetics and proteostasis pathways distinct from mitophagy could be beneficial to treating the early stage of PD.

  • Open Access

    Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing

    by International Parkinson’s Disease Genetics Consortium (IPGDC), Iris E. Jansen, Hui Ye, Sasja Heetveld, Marie C. Lechler, Helen Michels, Renée I. Seinstra, Steven J. Lubbe, Valérie Drouet, Suzanne Lesage, et al.

    Whole-exome sequencing (WES) has been successful in identifying genes that cause familial Parkinson’s disease (PD). However, until now this approach has not been deployed to study large cohorts of unrelated participants. To discover rare PD susceptibility variants, we performed WES in 1148 unrelated cases and 503 control participants. Candidate genes were subsequently validated for functions relevant to PD based on parallel RNA-interference (RNAi) screens in human cell culture and Drosophila and C. elegans models. Assuming autosomal recessive inheritance, we identify 27 genes that have homozygous or compound heterozygous loss-of-function variants in PD cases. Definitive replication and confirmation of these findings were hindered by potential heterogeneity and by the rarity of the implicated alleles. We therefore looked for potential genetic interactions with established PD mechanisms. Following RNAi-mediated knockdown, 15 of the genes modulated mitochondrial dynamics in human neuronal cultures and four candidates enhanced α-synuclein-induced neurodegeneration in Drosophila. Based on complementary analyses in independent human datasets, five functionally validated genes—GPATCH2L, UHRF1BP1L, PTPRH, ARSB, and VPS13C—also showed evidence consistent with genetic replication. By integrating human genetic and functional evidence, we identify several PD susceptibility gene candidates for further investigation. Our approach highlights a powerful experimental strategy with broad applicability for future studies of disorders with complex genetic etiologies.